# Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer

> **NCT00281996** · PHASE1 · TERMINATED · sponsor: **Northwestern University** · enrollment: 19 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Imatinib mesylate

## Key facts

- **NCT ID:** NCT00281996
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-03
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Closed to accrual to allow enrollment on another more promising trial.
- **Last updated:** 2011-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00281996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00281996, "Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00281996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*